Turn Therapeutics Inc. (TTRX)
Health Care · Topical immunomodulators for inflammatory skin disease · NASDAQ
Turn Therapeutics is developing a non-systemic topical immunomodulator (GX-03) containing polyhexanide for moderate-to-severe eczema and onychomycosis, with topline results expected mid-2026.
What Turn Therapeutics Inc. does
Turn Therapeutics is a clinical-stage dermatology company developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases. The company's lead program, GX-03, is a topical formulation containing polyhexanide (PHMB) being evaluated in a randomized, double-blind clinical trial for moderate-to-severe eczema, with topline results expected mid-2026. GX-03 is also being advanced for onychomycosis (fungal nail infections) based on preclinical data demonstrating nail penetration and antifungal activity. The company leverages a lean operational model with contractors and vendors while pursuing FDA drug approvals for two skin conditions that currently require pharmaceutical approval for marketing.
Themes: dermatology drug development, non-systemic topical therapy, inflammatory skin disease, antimicrobial drug development, medical device licensing
Fundamentals
- Price$9.63 as of 2026-08-26 close
- Market cap$287M as of 2026-08-26
- P/En/a earnings data not available
- ROE-117.3% as of 2026-08-27
- Debt / equity0.97 as of 2026-08-27
- Beta0.70 as of 2026-08-27
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How TTRX compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-27
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How Turn Therapeutics Inc. looks technically
Turn Therapeutics Inc. (TTRX) is trading 90.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average has held above its 200-day average for at least 13 trading days — a long-sustained "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative). It made a new 20-day high about 11 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 90.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +90.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $8.65 | $8.65 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.07 | $5.07 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 10.9529. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average has held above its 200-day average for at least 13 trading days — a long-sustained "golden cross", a bullish long-term signal | at least 13 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 23 (a reading of 25+ marks a strong trend) | 22.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($9.04 to $10.95) — its "stochastic" reading is 31 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 30.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 9 trading days ago (its momentum flipped negative) | 9 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $26.50 | $26.50 |
|---|---|---|
| From the 52-week high | it is 63.7% below its 52-week high (its highest price of the past year) | -63.7% |
| Above the 52-week low | it is 274.7% above its 52-week low (its lowest price of the past year) | +274.7% |
| Below the 52-week high | it is 63.7% below its highest point of the past year | 63.7% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $26.50 (set on 2025-10-09) | $26.50 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 63.7% below its all-time high | -63.7% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $2.57 (set on 2025-11-20) | $2.57 |
| Above the all-time low | it is 274.7% above its all-time low | +274.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7418 between its high and its low — about 7.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7418 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.48 and $10.72 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.48 – $9.60 – $10.72 |
| Typical daily range (% of price) | its price moves about 7.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.7% |
| Stretch from the 200-day average | it is trading 6.2 daily ranges above its 200-day average price (90.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 2 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 2 sessions ago |
|---|---|---|
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-26 3.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +3.1% |
|---|---|---|
| Open gap | it gapped 2.7% above the previous close 59 sessions ago and has not traded back through the level it left behind at 4.05 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.7% |
| Gap filled | a 3.1% gap up opened on 2026-08-26 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 9.1 percentage points (the stock gained 12.8% while the market gained 3.7%) | +9.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 85.0 percentage points (the stock gained 87.7% while the market gained 2.7%) | +85.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 139.6 percentage points (the stock gained 150.8% while the market gained 11.1%) | +139.6% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 8.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-21 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 14.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +8.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 40% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $6.90 — a volume-weighted average of daily closes over 153 sessions, not a true tick-by-tick VWAP. | +39.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $9.81 — a volume-weighted average of daily closes over 11 sessions, not a true tick-by-tick VWAP. | -1.8% |
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $10.95.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 5 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-26.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Gapped up at the open (3%+) · Most volatile (6%+ typical daily range) · Stretched far above its 200-day average (6+ daily ranges) · Under water since its last earnings report (below the anchored VWAP) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-26. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 1 analyst
- Mean price target$26.00 range $26.00 – $26.00
Analyst estimates, as of 2026-08-25. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Heavy reliance on the success of the lead drug candidate, GX-03, which is still in clinical development.","Potential difficulty in obtaining FDA approval for PHMB as an active pharmaceutical ingredient for the first time in the United States.","History of net losses and reliance on continued capital raises to fund research and development activities."]
What changed in the latest 10-Q
AI-assisted comparison of TTRX's 10-Q filed 2026-05-11 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing: Reference to Annual Report on Form 10-K for year ended December 31, 2025, filed March 31, 2026 (replacing prospectus reference)
- In newer filing: Specific mention of interim assessment at approximately 50% trial completion with topline results expected mid-2026
- In newer filing: Description of Independent Interim Assessment Committee (IAC) powers including pre-written statements on conditional probability and ability to increase enrollment up to 200%
- In newer filing: Statement that adaptive trial design does not impact statistical significance because interim assessment committee is fully independent
- In newer filing: Description of GX-03 in-vivo studies demonstrating nail-plate penetration and significant reduction of fungal burden for onychomycosis
- In newer filing: Explicit statement that K183681 has recently been licensed to Medline Industries, LP under a license and supply agreement
- In newer filing: Cash position as of March 31, 2026 of approximately $11.22 million (versus $5.08 million at December 31, 2025)
- In newer filing: Funding runway extended to first quarter of 2027
- Removed:
- In older filing: Detailed description of PermaFusion platform technology and proprietary mixing process
- In older filing: Reference to Hexagen formulation and founder's personal journey developing topical ointment
- In older filing: Discussion of three FDA clearances for historical formula and extensive human utilization
- In older filing: Detailed description of intranasal vaccine partnership with global nonprofit organization and cold-storage benefits
- In older filing: Preclinical xenograft studies results for herpes zoster ophthalmicus (85% viral load reduction) and basal cell carcinoma (29% and 20% tumor reduction comparisons)
- In older filing: Reference to prospectus filed October 8, 2025
- In older filing: Net losses of $3.47 million and $1.45 million for nine months ended September 30, 2025 and 2024
- In older filing: Accumulated deficit of approximately $22.67 million as of September 30, 2025
- In older filing: Cash position as of September 30, 2025 of approximately $3.11 million and $0.9 million at December 31, 2024
- In older filing: Funding runway into first quarter of 2026
- Reworded:
- Older: 'We are a pharmaceutical and medical device development company built around a proprietary platform technology' changed to newer: 'Turn Therapeutics is a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies'
- Older: Emphasis on PermaFusion platform as central to company identity removed; newer focuses on GX-03 as lead program
- Older: 'Hexagen' product name and formulation details removed in newer version
- Older: Overview shifted from platform technology discussion to product-specific focus on GX-03 and dermatologic conditions
- Older: Broader exploratory programs (herpes zoster, basal cell carcinoma) removed from core discussion in newer
- Older: 'intranasal vaccine platform' described as partnership program; newer describes as 'exploratory work' not part of 'primary dermatology development path'
- Notes:
- The older filing references September 30, 2025 interim financial data while newer filing references March 31, 2026 interim data, making some comparisons reflect natural progression rather than restatement
- The older and newer filings represent different reporting periods (nine months and three months respectively), which affects net loss comparisons
- The shift from prospectus-based disclosure to Annual Report on Form 10-K reference reflects transition from direct listing prospectus to regular periodic reporting
Risk Factors
- Added:
- Newer filing (2026-05-11) adds 'Deferred Offering Cost' line item of $6,195,192 in assets (not present in older filing)
- Newer filing (2026-05-11) adds 'Derivative liability instruments' line item of $2,767,462 in current liabilities (not present in older filing)
- Newer filing (2026-05-11) adds 'Long-term debt, net' line item of $5,936,514 in liabilities (not present in older filing)
- Newer filing (2026-05-11) adds 'Direct Listing' section noting October 8, 2025 Nasdaq listing under ticker TTRX
- Newer filing (2026-05-11) adds 'Avenue Capital Agreement' equity issuance of 342,857 shares for $1,050,967
- Newer filing (2026-05-11) adds 'Avenue Capital Loan Agreement' financing of $6,716,561
- Newer filing (2026-05-11) reports 'Net gain from change in fair value of derivative liability instrument' of $697,561 in other income
- Newer filing (2026-05-11) reports 'Amortization of deferred offering cost' of $477,647
- Removed:
- Older filing (2025-11-13) reports 'Derivative liability instruments' of $3,028,401 in current liabilities; not present in newer filing balance sheet structure
- Older filing (2025-11-13) shows nine months ended September 30 operating data; newer filing shows only three months ended March 31
- Reworded:
- Business description changed from 'pharmaceutical and medical device development company' (older) to 'clinical-stage biotechnology and medical device development company' (newer)
- Dermatological focus changed from 'moderate to severe eczema' (older) to 'moderate-to-severe atopic dermatitis' (newer)
- Vaccine development description changed from 'in partnership with a global nonprofit, with sufficient thermostability to overcome deep-freeze supply chain issues' (older) to 'with sufficient thermostability for rapid deployment for pandemic response' (newer)
- FDA reference changed from 'Federal Drug Administration' (older) to 'Food and Drug Administration' (newer)
- Section title changed from 'NATURE OF OPERATIONS' (older) to 'ORGANIZATION AND DESCRIPTION OF BUSINESS' (newer)
- Notes:
- The two filings cover different reporting periods (March 31, 2026 vs. September 30, 2025), limiting direct comparability of certain line items
- Newer filing includes 'Deferred Offering Cost' and long-term debt that do not appear in older filing, suggesting material financing activities occurred between periods
- Some financial statement formatting and presentation differences exist between the two filings
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
Most recent open-market transaction: 2025-12-12. As of 2026-08-27.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TTRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
2 institutional 13F filers reported holding TTRX as of 2025-12-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 2
- Reported shares held 51,142
- Reported value $201,499
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TTRX had 84,329 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TTRX had 0.28% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1 days to cover at the same settlement.
- Reported short interest (shares) 84,329
- Short interest (% of shares outstanding) 0.28%
- Prior settlement (shares) 57,729
- Reported change 46.08%
- Days to cover (reported) 1
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Pfizer (PFE)
- Eli Lilly (LLY)
- Incyte (INCY)
- Arcutis Biotherapeutics (ARQT)
- Dermavant Sciences (DMVT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TTRX vs…
Frequently asked questions
What does Turn Therapeutics Inc. (TTRX) do?
Turn Therapeutics is a clinical-stage dermatology company developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases. The company's lead program, GX-03, is a topical formulation containing polyhexanide (PHMB) being evaluated in a randomized, double-blind clinical trial for moderate-to-severe eczema, with topline results expected mid-2026.
What sector is Turn Therapeutics Inc. (TTRX) in?
Turn Therapeutics Inc. (TTRX) is classified in the Health Care sector. Its industry is Topical immunomodulators for inflammatory skin disease. It trades on NASDAQ.
Who are Turn Therapeutics Inc.'s (TTRX) competitors?
Notable peers of Turn Therapeutics Inc. (TTRX) include Sanofi, Pfizer, Eli Lilly, Incyte and Arcutis Biotherapeutics. This peer set is informational only — not financial advice.
Is Turn Therapeutics Inc. (TTRX) overbought or oversold right now?
Turn Therapeutics Inc. (TTRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-26). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TTRX come from?
Fundamentals and prices come from market data, as of 2026-08-27; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-27. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-26.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.